Biomarkers
RET Fusion
Also known as: RET rearrangement, RET-positive
Definition
A chromosomal rearrangement involving the RET gene, targetable with selective RET inhibitors.
Detailed Explanation
RET fusions occur in 1-2% of NSCLC, 10-20% of papillary thyroid cancer, and rarely in other cancers. Historically treated with multi-kinase inhibitors with significant toxicity. Now treated with selective RET inhibitors: selpercatinib (Retevmo) and pralsetinib (Gavreto) with better efficacy and tolerability.